Published in Nat Rev Immunol on September 18, 2009
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Immunological mechanisms of vaccination. Nat Immunol (2011) 3.35
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol (2013) 2.87
Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog (2011) 1.62
Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med (2010) 1.54
Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A (2012) 1.46
Predicting network activity from high throughput metabolomics. PLoS Comput Biol (2013) 1.44
Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med (2011) 1.30
Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio (2014) 1.26
How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol (2010) 1.23
Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One (2011) 1.22
Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med (2011) 1.19
Systems biology approaches to new vaccine development. Curr Opin Immunol (2011) 1.17
Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci U S A (2014) 1.16
Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin Immunol (2013) 1.11
Development of newborn and infant vaccines. Sci Transl Med (2011) 1.09
The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines (2013) 1.08
The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. Genes Immun (2011) 1.06
Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS (2012) 1.01
Human endogenous retroviruses and cancer prevention: evidence and prospects. BMC Cancer (2013) 0.99
Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol (2013) 0.98
Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol (2014) 0.98
Immunogenomics and systems biology of vaccines. Immunol Rev (2011) 0.97
Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog (2013) 0.97
Dynamics of the cytotoxic T cell response to a model of acute viral infection. J Virol (2015) 0.96
Gene-expression measurement: variance-modeling considerations for robust data analysis. Nat Immunol (2012) 0.94
Approaches to vaccines against Orientia tsutsugamushi. Front Cell Infect Microbiol (2013) 0.94
Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines (2012) 0.93
Immunity to viruses: learning from successful human vaccines. Immunol Rev (2013) 0.92
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cell Mol Immunol (2015) 0.92
Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine (2015) 0.90
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med (2015) 0.89
TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. J Virol (2010) 0.88
T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs. PLoS Negl Trop Dis (2013) 0.88
The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy. Clin Dev Immunol (2010) 0.88
New approaches to design HIV-1 T-cell vaccines. Curr Opin HIV AIDS (2010) 0.88
CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol (2014) 0.87
Systems analysis of West Nile virus infection. Curr Opin Virol (2014) 0.86
Systems biology of natural simian immunodeficiency virus infections. Curr Opin HIV AIDS (2012) 0.85
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine (2014) 0.84
Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis (2014) 0.84
Translational research in infectious disease: current paradigms and challenges ahead. Transl Res (2012) 0.83
Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS One (2013) 0.83
Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS One (2013) 0.82
Innate immune sensing and response to influenza. Curr Top Microbiol Immunol (2015) 0.82
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications. Front Immunol (2014) 0.82
The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study. Emerg Themes Epidemiol (2015) 0.81
Omic personality: implications of stable transcript and methylation profiles for personalized medicine. Genome Med (2015) 0.81
Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses. MBio (2016) 0.81
Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines (2016) 0.80
Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. Rev Med Virol (2015) 0.79
Gene signatures related to HAI response following influenza A/H1N1 vaccine in older individuals. Heliyon (2016) 0.78
Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation. Chem Commun (Camb) (2013) 0.78
Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes Attenuation In Vivo while Inducing a Strong Neutralizing Antibody Response. J Virol (2015) 0.78
Yellow Fever 17DD Vaccine Virus Infection Causes Detectable Changes in Chicken Embryos. PLoS Negl Trop Dis (2015) 0.77
Some unmet challenges in the immunology of viral infections. Discov Med (2010) 0.77
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anti-Cancer Immunity. Cancer Immunol Res (2017) 0.77
Modulation of Innate Immune Responses via Covalently Linked TLR Agonists. ACS Cent Sci (2015) 0.76
The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies. BMC Cancer (2014) 0.76
Molecular determinants of plaque size as an indicator of dengue virus attenuation. Sci Rep (2016) 0.75
Modeling HIV vaccine trials of the future. Curr Opin HIV AIDS (2016) 0.75
A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS One (2016) 0.75
Live attenuated influenza virus increases pneumococcal translocation and persistence within the middle ear. J Infect Dis (2014) 0.75
Systems biology from virus to humans. J Anal Sci Technol (2015) 0.75
Cryptosporidium hominis gene catalog: a resource for the selection of novel Cryptosporidium vaccine candidates. Database (Oxford) (2016) 0.75
T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models. Viruses (2017) 0.75
Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. J Gen Virol (2014) 0.75
Development of a Recombinant Yellow Fever Vector Expressing a HIV Clade C Founder Envelope gp120. J Virol Methods (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol (2007) 33.06
Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev (1999) 13.24
Taking dendritic cells into medicine. Nature (2007) 11.82
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol (2008) 7.18
Innate immunity to virus infection. Immunol Rev (2009) 7.04
Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2006) 5.05
The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol (2005) 4.83
Mammalian stress granules and processing bodies. Methods Enzymol (2007) 4.76
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21
THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION. J Exp Med (1937) 3.65
Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol (2008) 3.43
THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS. J Exp Med (1937) 3.38
Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci U S A (1987) 2.26
Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis (2008) 2.14
Yellow fever vaccine. Expert Rev Vaccines (2005) 2.13
Functional properties and genomics of glucose transporters. Curr Genomics (2007) 2.08
Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol (1998) 1.90
Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses. EMBO J (2006) 1.79
Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med (2005) 1.71
Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol (2005) 1.70
Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol (2009) 1.60
BLyS and B cell homeostasis. Semin Immunol (2006) 1.58
Different chemokine expression in lethal and non-lethal murine West Nile virus infection. J Med Virol (2004) 1.55
Dengue virus induces expression of CXC chemokine ligand 10/IFN-gamma-inducible protein 10, which competitively inhibits viral binding to cell surface heparan sulfate. J Immunol (2006) 1.38
Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine (2005) 1.31
Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. J Gen Virol (1996) 1.15
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology (2001) 1.14
Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine (2007) 1.13
Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology (1997) 1.07
Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine (2008) 1.05
Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis (2008) 0.96
Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine (2008) 0.94
Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol (2007) 0.92
Concurrent and consecutive infection and immunisation with yellow fever and UGMP-359 viruses. Arch Virol (1975) 0.78